Emergence of B.1.1.318 SARS-CoV-2 viral lineage and high incidence of alpha B.1.1.7 variant of concern in the Republic of Gabon
•SARS-CoV-2 diversity in the Republic of Gabon between February and May 2021•Emergence of B.1.1.318 SARS-CoV-2 in the Republic of Gabon•High prevalence of the alpha VOC (B.1.1.7) between February and May 2021•SARS-CoV-2 variants associated with high transmission were detected Variants of concern (VO...
Gespeichert in:
Veröffentlicht in: | International journal of infectious diseases 2022-01, Vol.114, p.151-154 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •SARS-CoV-2 diversity in the Republic of Gabon between February and May 2021•Emergence of B.1.1.318 SARS-CoV-2 in the Republic of Gabon•High prevalence of the alpha VOC (B.1.1.7) between February and May 2021•SARS-CoV-2 variants associated with high transmission were detected
Variants of concern (VOCs) associated with relatively high transmissibility appear to be rapidly spreading in Gabon. Therefore, it is imperative to understand the distribution of several VOCs in the population, which could have implications for transmissibility and vaccine efficacy.
Between February and May 2021, SARS-CoV-2 genomes were sequenced using the Oxford nanopore MinION method and the respective genome diversity was elucidated. Phylogenetic analysis was performed and genomes were classified using pangolin lineages.
The results highlighted an increase (46%) in the alpha VOC (B.1.1.7) in the Gabonese population over the study period. In addition, an increase (31%) in the B.1.1.318 lineage, which is associated with high transmission and impaired vaccine efficacy (D614G+E484K+Y144del), was detected.
With the second wave ongoing, these findings highlight the need for surveillance of the SARS-CoV-2 genome in the Republic of Gabon and should provide useful guidance to policymakers in selecting an appropriate vaccine for this population. |
---|---|
ISSN: | 1201-9712 1878-3511 1878-3511 |
DOI: | 10.1016/j.ijid.2021.10.057 |